Supplementary materials: The societal impact of early intensified treatment in patients with Type 2 diabetes mellitus

<b>These are peer-reviewed supplementary materials for the article '</b><b>The societal impact of early intensified </b><b>treatment in patients with Type 2 diabetes </b><b>mellitu</b>s<b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Figure S1: </b>Fitted parametric distributions for time to treatment failure in the early intensified treatment group<b>Figure S2: </b>Fitted parametric distributions for time to treatment failure in the stepwise approach group<b>Table S1: </b>6-month probabilities of complication events per treatment scenario [1,2]<b>Table S2: </b>Input parameters for the socioeconomic valuation<b>Table S3: </b>Parameter Variation in DSA<b>Table S4: </b>Parameter Variation in PSA<b>Table S5: </b>Age and gender distribution<b>Table S6: </b>Number of total complication events per treatment strategy<b>Table S7: </b>Avoided productivity losses per avoided event for each complication<b>Table S8: </b>Societal Impact variation when parameters were varied to their lower and upper bound in the DSA<b>Aim:</b> The current study estimates the societal impact of early intensified treatment compared with initial monotherapy with subsequent treatment intensification in newly diagnosed adults with Type 2 diabetes mellitus in Mexico. <b>Methods:</b> An individual patient-level simulation and a static cohort model were employed to simulate the treatment pathway and the probability of experiencing complications of diabetes. The avoided number of events was translated into avoided productivity losses, which were monetized using wages. <b>Results: </b>Patients on early intensified treatment experienced approximately 13,000 fewer complication events over 10 years. This was translated into a societal impact of $54 million (USD). <b>Conclusion:</b> Early treatment intensification is likely to be of particular benefit to health outcomes and productivity losses.

本内容为发表于《比较效果研究杂志》（*Journal of Comparative Effectiveness Research*）的论文《2型糖尿病患者早期强化治疗的社会影响》（原英文标题：The societal impact of early intensified treatment in patients with Type 2 diabetes mellitus）的同行评议补充材料。
图S1：早期强化治疗组治疗失败时间的拟合参数分布
图S2：阶梯治疗组治疗失败时间的拟合参数分布
表S1：各治疗场景下6个月并发症事件发生概率[1,2]
表S2：社会经济价值评估输入参数
表S3：确定性敏感性分析（Deterministic Sensitivity Analysis, DSA）中的参数变动
表S4：概率敏感性分析（Probabilistic Sensitivity Analysis, PSA）中的参数变动
表S5：年龄与性别分布
表S6：各治疗策略的总并发症事件数
表S7：每避免1例各类并发症所减少的生产力损失
表S8：将参数调整至确定性敏感性分析上下限后的社会影响变动

研究目的：本研究评估墨西哥新诊断成人2型糖尿病患者中，早期强化治疗对比初始单药治疗后续阶梯强化治疗的社会影响。

研究方法：本研究采用个体患者层面模拟与静态队列模型，模拟糖尿病患者的治疗路径及并发症发生概率。将避免的事件数转化为避免的生产力损失，并以工资水平将其货币化。

研究结果：接受早期强化治疗的患者在10年内的并发症事件数约减少13000例，由此带来的社会影响折合5400万美元（USD）。

研究结论：早期强化治疗对改善健康结局及减少生产力损失具有显著益处。